HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $190 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Neurocrine Biosciences, maintaining a price target of $190.
November 01, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Neurocrine Biosciences, maintaining a price target of $190.
The reiteration of a Buy rating and maintenance of a $190 price target by HC Wainwright & Co. is a positive signal for investors, suggesting confidence in the company's future performance. This could lead to increased investor interest and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100